Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3873862 in Amyotrophic Lateral Sclerosis
NCT07883590Phase 1Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2026
- Primary completion
- Nov 2027
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of LY3873862 in amyotrophic lateral sclerosis (ALS) (3 cohorts), sponsored by Eli Lilly and Company. Primary endpoint: Treatment Emergent Adverse Events at Day 28. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
LY3873862
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07883590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07883590.